Skip to main content
Premium Trial:

Request an Annual Quote

Odyssey Thera Signs Cell-Based Assay Services Agreement with Lexicon Genetics

NEW YORK, June 20 (GenomeWeb News) - Odyssey Thera has signed a services agreement with Lexicon Genetics under which it will characterize the pathway activity of certain Lexicon compounds in human cells.


Odyssey Thera said it will apply its protein-fragment complementation assay (PCA) technology to study the on-pathway and off-pathway activities of compounds in living human cells.


The company said that it uses a database of known drugs and toxic compounds in order to compare the activity of novel compounds with the activities of marketed and withdrawn agents and toxicants.


Financial terms of the agreement with Lexicon were not provided.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.